Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.

Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. Abstract Text:

P A Bakumov,I V Shchepotkin,Yu L Dugina,S A Sergeeva,O I Epstein,

Clinical efficiency and safety of Epigam containing antibodies to histamine in ultralow doses were studied during the therapy of patients with exacerbation of peptic ulcer disease of the stomach and duodenum associated with Helicobacter pylori infection. We examined 20 patients (18-50 years) with ulcerative lesions of the mucosal layer in the stomach and duodenum and H. pylori infection. Epigam (1 tablet, 6 times a day) or H2 receptor blocker ranitidine (150 mg, 2 times a day) were given in combination with amoxicillin (500 mg, 3 times a day, 14 days) and metronidazole (500 mg, 2 times a day, 14 days) for 28 days. The efficiency of treatment was determined before and 1, 2, 3, and 4 weeks after the start of therapy. The symptoms of peptic ulcer disease and time of ulcer healing underwent similar changes in patients of both groups. However, after ranitidine therapy pain syndrome disappeared more rapidly than in patients receiving Epigam. Epigam did not cause undesirable side effects. Our results indicate that Epigam is an efficient and safe preparation that may be used for combination therapy of patients with peptic ulcer disease of the stomach and duodenum.

Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. Publishing Authors By Initials

PA Bakumov,IV Shchepotkin,YL Dugina,SA Sergeeva,OI Epstein,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Bulletin of experimental biology and medicine

VOLUME: 135 Suppl 1

Page Numbers: 159-62

Journal Abbreviation: Bull. Exp. Biol. Med.

ISSN: 0007-4888

DAY: 1

MONTH: 09

YEAR: 2003

Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372557

Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.

AFFILIATION: Volgograd Medical Academy; "Materia Medica Holding" Research-and-Production Company, Moscow.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bull Exp Biol Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum Related Publications

• A pharmacy benefit manager perspective.
• Analgesic and Antiinflammatory Activity of Antibodies to Histamine under Experimental Conditions.
• Antibodies to delta sleep-inducing Peptide in ultralow doses: study of the effect by enzyme immunoassay.
• Antiulcer Activity of Ultralow Doses of Antibodies to Histamine under Experimental Conditions.
• Changes in Immunological Parameters in Patients with Opium Abuse Receiving ANAR Therapy.
• Clinical efficiency of epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.
• Co-twin control designs for testing behavioral economic theories of child nutrition: methodological note.
• Coexistence, competition and hypercyclic interaction in some systems of biological interest.
• Effect of Potentiated Antibodies to Cyclophosphamide on the Development of Tumors and Effectiveness of Cytostatic Therapy under Experimental Conditions.
• Effect of Potentiated Solutions on Mercury(II) Signal in Inversion Voltammetry.
• Effect of Preparations from Potentiated Ethanol on the Content of Biogenic Monoamines and Metabolism of Ethanol in Tissues of Rats during Alcoholization.
• Effect of allotransplantation of embryonic brain tissues and administration of potentiated antibodies to bombesin on hemodynamics in rats with emotional hypertension.
• Effect of antibodies to morphine in ultralow doses on induction of long-term potentiation in hippocampal slices from rats with chronic morphine dependence.
• Effect of potentiated antibodies to morphine on behavioral reactions in rats with morphine dependence.
• Effects of Potentiated Antibodies Against Brain-Specific S100 Protein on Biogenic Amine Content and Lipid Peroxidation in Rats under Conditions of Alcoholization.
• Effects of ultralow doses of antibodies to prostate-specific antigen on morphological and functional state of rat prostate.
• Efficiency of ultralow doses of antibodies to s100 protein and delta sleep-inducing Peptide in rats with anxious depression.
• Impaza and sildenafil: comparison of clinical effectiveness in patients with erectile dysfunction.
• Membranotropic effects of antibodies to s100 protein in ultralow doses.
• Metallothionein and catalase sensitize to diabetes in nonobese diabetic mice: reactive oxygen species may have a protective role in pancreatic beta-cells.
• Potentiated Antibodies to Tumor Necrosis Factor-alpha in the Therapy of Patients with Rheumatoid Arthritis.
• Potentiated antibodies against morphine: effects on biogenic amines and lipid peroxidation in chronically morphinized rats.
• Potentiated cyclophosphane: experimental study of the effect on tumor development and efficiency of cytostatic therapy.
• Proproten-100 in the therapy of patients with the alcohol withdrawal syndrome.
• Regulatory activity of ultralow doses.
• Relationship between sex of parent and child on weight loss and maintenance in a family-based obesity treatment program.
• Reperfused myocardial infarction in mice: 3D mapping of late gadolinium enhancement and strain.
• The challenge of Down syndrome.
• Ultralow Doses of Anti-Idiotypic Antibodies to Human gamma-Interferon: Immunotropic Properties.
• Use of potentiated preparations to relieve alcohol and opium withdrawal syndromes.